Your search returned 3 results.

Sort
Results
1.
Adjuvant therapy for high-grade, uterus-limited leiomyosarcoma: results of a phase 2 trial (SARC 005). MedStar authors:
  • Priebat, Dennis A
PMID:
  • 23335221
Citation:
  • Cancer. 119(8):1555-61, 2013 Apr 15.
Institution:
  • Washington Cancer Institute
Medline publication type:
  • Clinical Trial, Phase II
  • Journal Article
  • Multicenter Study
  • Research Support, Non-U.S. Gov't
Form of publication:
  • Journal Article
All authors:
  • Araujo DM, Baker LH, George S, Hensley ML, Maki RG, Priebat DA, Soslow RA, Sutton G, Wathen JK
2.
Obatoclax mesylate, a pan-bcl-2 inhibitor, in combination with docetaxel in a phase 1/2 trial in relapsed non-small-cell lung cancer. MedStar authors:
  • Van Echo, David A
PMID:
  • 24346101
Year: 2014
Citation:
  • Journal of Thoracic Oncology: Official Publication of the International Association for the Study of Lung Cancer. 9(1):121-5, 2014 Jan.
Institution:
  • MedStar Health Research Institute
Medline publication type:
  • Clinical Trial, Phase I
  • Clinical Trial, Phase II
  • Journal Article
  • Research Support, Non-U.S. Gov't
Form of publication:
  • Journal Article
All authors:
  • Adams JW, Berger MS, Chiappori A, Edelman MJ, Haura EB, Malik S, Northfelt DW, Rosen P, Van Echo DA, Williams C
3.
Effect of adding mFOLFOX6 after neoadjuvant chemoradiation in locally advanced rectal cancer: a multicentre, phase 2 trial. MedStar authors:
  • Kumar, Anjali S
PMID:
  • 26187751
Citation:
  • Lancet Oncology. 16(8):957-66, 2015 Aug.
Institution:
  • MedStar Washington Hospital Center
Department:
  • Surgery/Colorectal Surgery
Medline publication type:
  • Clinical Trial, Phase II
  • Journal Article
  • Multicenter Study
  • Research Support, N.I.H., Extramural
Form of publication:
  • Journal Article
All authors:
  • Avila K, Cataldo PA, Chow OS, Coutsoftides T, Dietz DW, Fichera A, Garcia-Aguilar J, Herzig DO, Hunt SR, Kumar AS, Marcet JE, Oommen S, Patil S, Polite BN, Smith DD, Stamos MJ, Ternent CA, Timing of Rectal Cancer Response to Chemoradiation Consortium, Varma MG
Pages

Powered by Koha